继续或继续接受恩替卡韦治疗的乙型肝炎E抗原阴性非肝硬化

StephenW

The Incidence of Hepatitis B Surface Antigen Loss Between Hepatitis B E Antigen-Negative Noncirrhotic Patients Who Discontinued or Continued Entecavir Therapy
Chien-Hung Chen Chao-Hung Hung Jing-Houng Wang Sheng-Nan Lu Hsueh-Chou Lai Tsung-Hui Hu Chia-Hsin Lin Cheng-Yuan Peng
The Journal of Infectious Diseases, Volume 219, Issue 10, 15 May 2019, Pages 1624–1633, https://doi.org/10.1093/infdis/jiy697
Published:
17 January 2019

Abstract
Background

We compared rates of hepatitis B surface antigen (HBsAg) loss and hepatocellular carcinoma (HCC) development in hepatitis B e antigen (HBeAg)-negative patients without cirrhosis who continued or discontinued entecavir.
Methods

Patients who discontinued entecavir treatment for at least 12 months (discontinued group; n = 234) and patients who continued entecavir treatment for at least 4 years (continued group; n = 226) were recruited.
Results

In the discontinued group, the 5-year cumulative incidences of virological relapse (VR), clinical relapse (CR), and HBsAg loss were 71.9%, 58.9%, and 13%, respectively. Patients with sustained response, VR but no CR, and CR without retreatment were 49-, 13-, and 18-fold more likely to develop HBsAg loss than those with retreatment. Patients who discontinued entecavir therapy had a higher rate of HBsAg loss than those who continued entecavir therapy, in all and 360 propensity score (PS)-matched patients. Cox regression analysis revealed that the discontinued group was an independent predictor for HBsAg loss. There was no significant difference in HCC development between the 2 groups in all and PS-matched patients.
Conclusions

HBeAg-negative patients without cirrhosis who discontinued entecavir treatment exhibited a higher HBsAg loss rate without an increased risk of HCC compared to those who continued entecavir treatment.
hepatitis B virus, hepatitis B surface antigen, entecavir, hepatocellular carcinoma

StephenW

继续或继续接受恩替卡韦治疗的乙型肝炎E抗原阴性非肝硬化患者乙型肝炎表面抗原丢失的发生率
陈建红陈超红洪景厚王胜南陆雪L赖承辉胡家新林成元彭
Journal of Infectious Diseases，第219卷，第10期，2015年5月15日，第1624-1633页，https：//doi.org/10.1093/infdis/jiy697
发布时间：
2019年1月17日

抽象
背景

我们比较了继续或停用恩替卡韦的乙型肝炎e抗原（HBeAg）阴性无肝硬化患者的乙型肝炎表面抗原（HBsAg）丢失和肝细胞癌（HCC）发生率。
方法

招募停用恩替卡韦治疗至少12个月（停药组; n = 234）和继续接受恩替卡韦治疗至少4年（继续组; n = 226）的患者。
结果

在已停产的组中，病毒学复发（VR），临床复发（CR）和HBsAg损失的5年累积发生率分别为71.9％，58.9％和13％。具有持续反应，VR但没有CR和没有再治疗的CR的患者发生HBsAg丢失的可能性比再治疗患者高49,13和18倍。在所有和360倾向评分（PS）匹配的患者中，停用恩替卡韦治疗的患者的HBsAg消失率高于继续接受恩替卡韦治疗的患者。 Cox回归分析显示，停用组是HBsAg丢失的独立预测因子。在所有和PS匹配的患者中，两组之间的HCC发展没有显着差异。
结论

与继续接受恩替卡韦治疗的患者相比，停用恩替卡韦治疗的无肝硬化的HBeAg阴性患者表现出较高的HBsAg丢失率而没有增加的HCC风险。
乙型肝炎病毒，乙型肝炎表面抗原，恩替卡韦，肝细胞癌

小牡丹

与战友们的情况相符